^
    IDH1 mutation
    Cholangiocarcinoma
    ivosidenib
    Sensitive
    :
    A2
    Servier Press Release - 1d
    dMMR/MSI-H + TMB-L
    Cholangiocarcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    PTEN mutation + MSI-H/dMMR
    Cholangiocarcinoma
    PD1 inhibitor
    Resistant
    :
    C3
    Clin Cancer Res - 1wk
    BRCA1 S451Lfs*20
    Gallbladder Cancer
    olaparib
    Sensitive
    :
    C4
    Onco Targets Ther - 2wk
    FGFR2 rearrangement
    Cholangiocarcinoma
    pemigatinib
    Sensitive
    :
    A1
    FGFR2 fusion
    Cholangiocarcinoma
    pemigatinib
    Sensitive
    :
    A1
    No biomarker
    Gallbladder Cancer
    GC
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    GemOx
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    CAPOX
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    GEM-CAP
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    FP
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    CAPOX
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    XP
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    FP
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    XP
    Sensitive
    :
    A2
    No biomarker
    Cholangiocarcinoma
    gemcitabine + albumin-bound paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    capecitabine
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    cisplatin + gemcitabine + albumin-bound paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    5-fluorouracil + oxaliplatin
    Sensitive
    :
    A2
    No biomarker
    Cholangiocarcinoma
    gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    capecitabine
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    cisplatin + gemcitabine + albumin-bound paclitaxel
    Sensitive
    :
    A2
    BRAF V600E
    Biliary Tract Cancer
    trametinib + dabrafenib
    Sensitive
    :
    A2
    MSI-H/dMMR
    Biliary Tract Cancer
    pembrolizumab
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES